Technologies

Energy-based therapy, explained at the tissue level

How light and energy interact with tissue, what the evidence shows, and how objective testing reveals clinical response.

IPL and photobiomodulation treatment systems

PBM / LLLT

Photobiomodulation (Low-Level Light Therapy)

Photobiomodulation, also called low-level light therapy or LLLT, delivers non-thermal visible and near-infrared light to metabolically stressed retinal and periocular tissue. The name brings together research previously described as red light therapy, low-level laser irradiation and LLLT.

Common indications

Intermediate dry AMD
Geographic atrophy
Dry eye, chalazia and styes beyond IPL's reach
Amblyopia
Myopia control

Mechanism

Photons absorbed by cytochrome c oxidase in mitochondrial complex IV improve electron transport and ATP availability, reduce oxidative stress, and modulate inflammatory cytokines and the complement cascade - the same pathways targeted by emerging AMD injectables. The effect is non-pharmaceutical and additive: it complements rather than replaces existing treatment.

Clinical significance

Different visible and near-infrared wavelengths have different penetration profiles and tissue targets. The clinical question is how wavelength, energy exposure and disease stage relate to mitochondrial function and measurable tissue response.

IPL

Intense Pulsed Light

Broadband, filtered light applied to the periocular skin and lid margin to address the vascular and inflammatory drivers of meibomian gland dysfunction.

Common indications

Evaporative dry eye
Meibomian gland dysfunction
Ocular rosacea
Demodex-associated blepharitis

Mechanism

Selective absorption by haemoglobin and other chromophores reduces abnormal lid margin vasculature and inflammatory mediator load, improving meibum quality and gland expressibility.

Clinical significance

IPL addresses vascular and inflammatory contributors visible across the periocular and facial skin. Meibography, also called meibomian gland imaging, helps relate gland structure and dropout to symptoms, expressibility and realistic treatment expectations.

Radiofrequency

Controlled thermal energy delivered to periocular tissue, used alongside IPL where deeper and more uniform heating of the gland is required.

Common indications

Obstructive meibomian gland dysfunction
Mixed-mechanism dry eye
Periocular laxity

Mechanism

Tissue impedance converts radiofrequency current into heat, raising meibum to a workable temperature and stimulating dermal remodelling in the surrounding periocular skin.

Clinical significance

Its role is considered alongside IPL and photobiomodulation by matching the energy source to the tissue target, gland structure and inflammatory presentation.

Clinical systems

Tools used across the treatment pathway

Device selection follows the tissue target, condition stage and biological mechanism, not the other way around.

The evidence base

The clinical case is argued from trial data and case imagery, not enthusiasm. These are the findings training and support sessions return to most often.

2016 - first landmark trial

Yellow, red and infrared light over three weeks produced roughly one line of letter improvement sustained for three months, with measurable drusen volume reduction.

Recently published trials (Valeda)

51% of patients improved at least one line over two years, with drusen reduction and no geographic atrophy forming beneath resolving drusen - a historically unprecedented finding.

Drusen softening

Trial imagery shows hard drusen expanding at the edges, connecting with healthy tissue and being reabsorbed. Some patients plateau after one cycle and show their real gains in year two.

Amblyopia

A 2012 German study reported improvement in 90% of treated eyes, half gaining three or more lines. Multifocal ERG cases show improved retinal latency and amplitude - objective retinal change, not just perception.

Myopia control

Repeated red light therapy outperformed diluted atropine and orthokeratology on axial-length change in comparative trials.

Dry eye and chalazia

Pink-light photobiomodulation resolved bilateral chalazia in two visits after two weeks of failed topical therapy - with the patient still symptom-free at one year.

Measured follow-up

Objective testing

How OCT, drusen assessment, best-corrected acuity, contrast sensitivity, visual field or VEP measures, axial length, multifocal ERG and meibography can support baseline decisions and follow-up. Meibography is also described as meibomian gland imaging.

The practice side

Objective measurement, reimbursement and the patient conversation are what connect a biological effect to durable care in a real clinic.

Insurance billing and reimbursement

Patients matching the published trial criteria - intermediate AMD, acuity 20/32 to 20/70, age 50 or older, no central geographic atrophy - have been reimbursed around $127 per eye per session on Medicare Advantage plans and closer to $197 on standard Medicare and VA plans, billed under code 0936T with a modifier 50 when both eyes qualify on the same day.

The cash-pay conversation

Disclose the price within the first two sentences, before anxiety has room to build. Patients consistently react with relief because their anticipated cost was higher - and giving an explicit permission to wait for coverage makes them more likely to say yes, not less.

Measuring tissue response

Acuity alone does not tell the whole story. OCT, drusen assessment, contrast sensitivity and other objective tests help connect clinical change to the proposed mitochondrial, oxidative-stress and inflammatory effects of photobiomodulation.

Safety and precautions

The contraindication list is short: photosensitizing medications and supplements, active skin melanoma or recent facial carcinoma removal. Light-triggered migraines and seizure histories are accommodated with shorter initial sessions or neurologist sign-off; overproducing-cell cases are patched or deferred to dermatology.

Staff and scheduling

How technician-led treatment delivery, a consistent sequence, grouped appointments and priority for long-term maintenance patients fit around the doctor's baseline and reassessment decisions.

Clinical application is covered in training

Tissue response, patient selection, objective imaging and documentation are worked through directly with Dr. Brothers and applied to your own patients and equipment.

Talk with the institute Conditions in scope

Get in touch

Let's talk about implementing this in your clinic

Tell us what you already offer and what you want to add. Dr. Brothers and the institute team will come back to you with a practical next step.

Contact the institute See training options